Front Street Capital Management’s Sorrento Therapeutics, Inc. SRNE Stock Holding History

Front Street Capital Management’s Portfolio SRNE Stock Details SRNE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-24,000	Closed	-$21K	–	72
2022 Q4	$21K	Hold	24,000	–	–	0.01%	65
2022 Q3	$38K	Hold	24,000	–	–	0.01%	67
2022 Q2	$48K	Hold	24,000	–	–	0.01%	61
2022 Q1	$56K	Hold	24,000	–	–	0.01%	61
2021 Q4	$112K	Buy	+24,000	New	+$149K	0.02%	66

Other funds holding SRNE

Paloma Partners Greenwich, Connecticut $510M AUM 286.05% 1-Year Est. Return

OCM

Oaktree Capital Management Los Angeles, California $6.56B AUM 42.97% 1-Year Est. Return

OFA

Oaktree Fund Advisors Los Angles, California $56.9M AUM 80.32% 1-Year Est. Return

CGA

Crescent Grove Advisors Lake Forest, Illinois $1.04B AUM 17.78% 1-Year Est. Return

LCM

Lattice Capital Management Kirkland, Washington $56.9M AUM 49.15% 1-Year Est. Return

STB

S&T Bank Indiana, Pennsylvania $268M AUM 39.92% 1-Year Est. Return

GoalVest Advisory New York $539M AUM 27.49% 1-Year Est. Return

HFRG

Houlihan Financial Resource Group Ashburn, Virginia $257M AUM 14.19% 1-Year Est. Return

VFA

Valeo Financial Advisors Carmel, Indiana $4.74B AUM 27.69% 1-Year Est. Return

GBWM

Granite Bay Wealth Management Portsmouth, New Hampshire $470M AUM 15.4% 1-Year Est. Return

Front Street Capital Management's SRNE Position: Q1 2023 in Review

Front Street Capital Management sold out of Sorrento Therapeutics, Inc. (SRNE) in Q1 2023, closing a stake of 24,000 shares — an estimated $21K sold.

Front Street Capital Management first reported a position in SRNE in Q4 2021 and held it in 5 quarters. The position peaked at $112K in Q4 2021. 34 funds tracked by Wall St. Rank hold SRNE as of Q1 2023.

Front Street Capital Management reported no remaining Sorrento Therapeutics, Inc. position as of Q1 2023 after selling out during the quarter.
Front Street Capital Management sold 24,000 Sorrento Therapeutics, Inc. shares in Q1 2023, an estimated $21K.
Front Street Capital Management first reported a position in Sorrento Therapeutics, Inc. in Q4 2021 and held it in 5 quarters.
Front Street Capital Management's Sorrento Therapeutics, Inc. position peaked at $112K in Q4 2021.
34 funds tracked by Wall St. Rank held Sorrento Therapeutics, Inc. as of Q1 2023.

Based on Front Street Capital Management's 13F filing for Q1 2023, filed 16 May 2023.